Agency Emergency Processing Under Office of Management and Budget Review; Implementation of the Animal Generic Drug User Fee Act of 2008; User Fee Cover Sheet Form FDA 3728, 65384-65385 [E8-26162]
Download as PDF
65384
Federal Register / Vol. 73, No. 213 / Monday, November 3, 2008 / Notices
CBSA
code
Urban area
(constituent counties)
Wage
index
49700 .......
Mahoning County, OH.
Trumbull County, OH.
Mercer County, PA.
Yuba City, CA ............................................................................................................................................................................
Sutter County, CA.
Yuba County, CA.
Yuma, AZ ..................................................................................................................................................................................
Yuma County, AZ.
1.1137
49740 .......
0.9281
1 At this time, there are no hospitals in these urban areas on which to base a wage index. Therefore, the urban wage index value is based on
the average wage index of all urban areas within the State.
[FR Doc. E8–26142 Filed 10–30–08; 4:15 pm]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0572]
Agency Emergency Processing Under
Office of Management and Budget
Review; Implementation of the Animal
Generic Drug User Fee Act of 2008;
User Fee Cover Sheet Form FDA 3728
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for emergency processing under
the Paperwork Reduction Act of 1995
(the PRA). The proposed collection of
information concerns the burden hours
required for the Animal Generic Drug
User Fee Cover Sheet, Form FDA 3728
and the timeframe requirement under
the Animal Generic Drug User Fee Act
of 2008 (AGDUFA) (21 U.S.C. 379j–21)
for implementing the new user fee cover
sheet Form FDA 3728.
DATES: Fax written comments on the
collection of information by November
10, 2008.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–NEW and
‘‘Implementation of the Animal Generic
Drug User Fee Act of 2008 (21 U.S.C.
379j–21(a)); User Fee Cover Sheet Form
3728; Emergency Request.’’ Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3793.
SUPPLEMENTARY INFORMATION: FDA is
requesting emergency processing of this
proposed collection of information
under section 3507(j) of the PRA (44
U.S.C. 3507(j) and 5 CFR 1320.13). The
Federal Food, Drug, and Cosmetic Act
(the act), as amended by AGDUFA
authorizes FDA to collect user fees: (1)
For certain abbreviated applications for
a generic new animal drug, (2) on
certain generic new animal drug
products, and (3) on certain sponsors of
such abbreviated applications for
generic new animal drugs and/or
investigational submissions for generic
new animal drugs.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Implementation of the Animal Generic
Drug User Fee Act of 2008; User Fee
Cover Sheet Form FDA 3728 (21 U.S.C.
379j–21); Emergency Request
Section 741 of the act (21 U.S.C. 379j–
21), establishes three different kinds of
user fees: (1) Fees for certain types of
abbreviated applications for generic new
animal drugs, (2) annual fees for certain
generic new animal drug products, and
(3) annual fees for certain sponsors of
abbreviated applications for generic new
animal drugs and/or investigational
submissions for generic new animal
drugs. Because the submission of user
fees concurrently with applications is
required, the review of an application
cannot begin until the fee is submitted.
Form FDA 3728, the Animal Generic
Drug User Fee Cover Sheet, is designed
to provide the minimum necessary
information in order to: (1) Determine
whether a fee is required for review of
an application, (2) determine the
amount of fee required, and (3) account
for and track user fees.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 U.S.C. 379j–21.
sroberts on PROD1PC70 with NOTICES
Form FDA 3728
1 There
Annual Frequency
per Response
20
Total Annual
Responses
2
Hours per
Response
40
Total Hours
.08
are no capital costs or operating and maintenance costs associated with this collection of information.
Respondents to this collection of
information are generic new animal
VerDate Aug<31>2005
16:58 Oct 31, 2008
Jkt 217001
drug applicants. Based on FDA’s data
base system, there are an estimated 20
PO 00000
Frm 00101
Fmt 4703
Sfmt 4703
sponsors of new animal drugs
potentially subject to AGDUFA. The
E:\FR\FM\03NON1.SGM
03NON1
3.2
Federal Register / Vol. 73, No. 213 / Monday, November 3, 2008 / Notices
annual reporting burden estimates in
table 1 of this document are based on
FDA’s previous experience.
Dated: October 29, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–26162 Filed 10–31–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0565]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Guidance for
Industry on Formal Dispute
Resolution; Appeals Above the
Division Level
AGENCY:
Food and Drug Administration,
HHS.
sroberts on PROD1PC70 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the information collection contained in
the guidance for industry on formal
dispute resolution.
DATES: Submit written or electronic
comments on the collection of
information by January 2, 2009.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Berbakos, Office of
Information Management (HFA–710),
Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857,
301–796–3792.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
VerDate Aug<31>2005
16:58 Oct 31, 2008
Jkt 217001
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Guidance for Industry on Formal
Dispute Resolution; Appeals Above the
Division Level (OMB Control Number
0910–0430)—Extension
This information collection approval
request is for an FDA guidance on the
process for formally resolving scientific
and procedural disputes in the Center
for Drug Evaluation and Research
(CDER) and the Center for Biologics
Evaluation and Research (CBER) that
cannot be resolved at the division level.
The guidance describes procedures for
formally appealing such disputes to the
office or center level and for submitting
information to assist center officials in
resolving the issue(s) presented. The
guidance provides information on how
the agency will interpret and apply
provisions of the existing regulations
regarding internal agency review of
decisions (§ 10.75) and dispute
resolution during the investigational
new drug (IND) process (§ 312.48) and
the new drug application/abbreviated
new drug application (NDA/ANDA)
PO 00000
Frm 00102
Fmt 4703
Sfmt 4703
65385
process (§ 314.103). In addition, the
guidance provides information on how
the agency will interpret and apply the
specific Prescription Drug User Fee Act
(PDUFA) goals for major dispute
resolution associated with the
development and review of PDUFA
products.
Existing regulations, which appear
primarily in parts 10, 312, and 314 (21
CFR parts 10, 312, and 314), establish
procedures for the resolution of
scientific and procedural disputes
between interested persons and the
agency, CDER, and CBER. All agency
decisions on such matters are based on
information in the administrative file
(§ 10.75(d)). In general, the information
in an administrative file is collected
under existing regulations in parts 312
(OMB Control No. 0910–0014), 314
(OMB Control No. 0910–0001), and part
601 (21 CFR part 601) (OMB Control No.
0910–0338), which specify the
information that manufacturers must
submit so that FDA may properly
evaluate the safety and effectiveness of
drugs and biological products. This
information is usually submitted as part
of an IND, NDA, or biologics license
application (BLA), or as a supplement to
an approved application. While FDA
already possesses in the administrative
file the information that would form the
basis of a decision on a matter in
dispute resolution, the submission of
particular information regarding the
request itself and the data and
information relied on by the requestor
in the appeal would facilitate timely
resolution of the dispute. The guidance
describes the following collection of
information not expressly specified
under existing regulations: The
submission of the request for dispute
resolution as an amendment to the
application for the underlying product,
including the submission of supporting
information with the request for dispute
resolution.
Agency regulations (§§ 312.23(11)(d),
314.50, 314.94, and 601.2) state that
information provided to the agency as
part of an IND, NDA, ANDA, or BLA is
to be submitted in triplicate and with an
appropriate cover form. Form FDA 1571
must accompany submissions under
INDs and Form FDA 356h must
accompany submissions under NDAs,
ANDAs, and BLAs. Both forms have
valid OMB control numbers as follows:
FDA Form 1571 - OMB Control No.
0910–0014, and FDA Form 356h - OMB
Control No. 0910–0338.
In the guidance document, CDER and
CBER ask that a request for formal
dispute resolution be submitted as an
amendment to the application for the
underlying product and that it be
E:\FR\FM\03NON1.SGM
03NON1
Agencies
[Federal Register Volume 73, Number 213 (Monday, November 3, 2008)]
[Notices]
[Pages 65384-65385]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-26162]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0572]
Agency Emergency Processing Under Office of Management and Budget
Review; Implementation of the Animal Generic Drug User Fee Act of 2008;
User Fee Cover Sheet Form FDA 3728
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for emergency processing under the
Paperwork Reduction Act of 1995 (the PRA). The proposed collection of
information concerns the burden hours required for the Animal Generic
Drug User Fee Cover Sheet, Form FDA 3728 and the timeframe requirement
under the Animal Generic Drug User Fee Act of 2008 (AGDUFA) (21 U.S.C.
379j-21) for implementing the new user fee cover sheet Form FDA 3728.
DATES: Fax written comments on the collection of information by
November 10, 2008.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974, or e-mailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-NEW and
``Implementation of the Animal Generic Drug User Fee Act of 2008 (21
U.S.C. 379j-21(a)); User Fee Cover Sheet Form 3728; Emergency
Request.'' Also include the FDA docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-3793.
SUPPLEMENTARY INFORMATION: FDA is requesting emergency processing of
this proposed collection of information under section 3507(j) of the
PRA (44 U.S.C. 3507(j) and 5 CFR 1320.13). The Federal Food, Drug, and
Cosmetic Act (the act), as amended by AGDUFA authorizes FDA to collect
user fees: (1) For certain abbreviated applications for a generic new
animal drug, (2) on certain generic new animal drug products, and (3)
on certain sponsors of such abbreviated applications for generic new
animal drugs and/or investigational submissions for generic new animal
drugs.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Implementation of the Animal Generic Drug User Fee Act of 2008; User
Fee Cover Sheet Form FDA 3728 (21 U.S.C. 379j-21); Emergency Request
Section 741 of the act (21 U.S.C. 379j-21), establishes three
different kinds of user fees: (1) Fees for certain types of abbreviated
applications for generic new animal drugs, (2) annual fees for certain
generic new animal drug products, and (3) annual fees for certain
sponsors of abbreviated applications for generic new animal drugs and/
or investigational submissions for generic new animal drugs. Because
the submission of user fees concurrently with applications is required,
the review of an application cannot begin until the fee is submitted.
Form FDA 3728, the Animal Generic Drug User Fee Cover Sheet, is
designed to provide the minimum necessary information in order to: (1)
Determine whether a fee is required for review of an application, (2)
determine the amount of fee required, and (3) account for and track
user fees.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 U.S.C. 379j- Respondents per Response Responses Response Total Hours
-------21.------------------------------------------------------------------------------------------------------
Form FDA 3728 20 2 40 .08 3.2
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Respondents to this collection of information are generic new
animal drug applicants. Based on FDA's data base system, there are an
estimated 20 sponsors of new animal drugs potentially subject to
AGDUFA. The
[[Page 65385]]
annual reporting burden estimates in table 1 of this document are based
on FDA's previous experience.
Dated: October 29, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-26162 Filed 10-31-08; 8:45 am]
BILLING CODE 4160-01-S